Claims for Patent: 8,980,541

Summary for Patent: 8,980,541

Title:	Evaluation and preservation solution
Abstract:	An evaluation and preservation solution for human and animal organs, tissues and parts thereof is described, wherein it comprises serum albumin at a concentration of 55-105 g/L, a scavenger and coating compound, preferably dextran compounds and derivatives thereof having essentially the same structure at a concentration of 1-55 g/L weight, and a physiological serum concentration of salts and nutrients in a physiologically acceptable medium.
Inventor(s):	Steen; Stig (Lund, SE)
Assignee:	XVIVO Perfusion AB (Goteborg, SE)
Application Number:	13/178,655
Patent Claims:	1. A method of perfusing an organ, tissue, or part thereof, of an animal or human, the method comprising: (1) evaluating the organ, tissue, or part thereof; and (2) perfusing the organ, tissue, or part thereof at normothermia by recirculation with a solution; wherein the solution comprises: (a) a colloidosmotically active substance that is too large to pass out through semipermeable capillary walls of the animal or human and that is present at a concentration that provides the oncotic pressure of serum albumin at a concentration of 55-105 g/L; (b) a scavenger and coating compound, which coats the capillary endothelium of the organ, tissue, or parts thereof, at a concentration of 1-55 g/L; (c) a physiological serum concentration of a salt; and (d) a nutrient for the organ, tissue, or part thereof, in a physiologically acceptable medium; and further wherein the evaluating comprises measuring evaluation parameters of the organ, tissue, or part thereof for transplantation thereof; the solution provides an oncotic pressure higher than an applied hydrostatic pressure in the organ, tissue, or part thereof, and prevents oedema formation; and the organ, tissue, or part thereof is connected to a heart-lung machine during the perfusion. 2. The method of claim 1, wherein the organ is a lung, a heart, a kidney, a liver, a pancreas, or small bowels. 3. The method of claim 1, further comprising preserving the organ, tissue or part thereof in said solution until the transplantation. 4. The method of claim 1, wherein the organ is a lung. 5. The method of claim 1, wherein the organ, tissue, or part thereof is harvested from a non-heart-beating animal or human donor, and the evaluating further comprises evaluating if the organ, tissue, or part thereof is acceptable for transplantation; and further comprising transplanting the organ, tissue, or part thereof into a receiver body. 6. The method of claim 5, further comprising preserving the organ, tissue, or part thereof in the solution until the transplantation. 7. The method of claim 5, wherein the organ, tissue, or part thereof is auto-, allo- or xenotransplanted. 8. The method of claim 1, wherein the colloidosmotically active substance has a negative charge and a molecular weight of about 69 kDa. 9. The method of claim 1, wherein the colloidosmotically active substance is a hyaluronic acid-based compound having a molecular weight of about 69 kDa. 10. The method of claim 1, wherein the colloidosmotically active substance is present in the solution at a concentration that provides the oncotic pressure of serum albumin at a concentration of 65-85 g/L. 11. The method of claim 1, wherein the colloidosmotically active substance is present in the solution at a concentration that provides the oncotic pressure of serum albumin at a concentration of 70 g/L. 12. The method of claim 1, wherein the scavenger and coating compound has a molecular weight ranging from 1 to 250 kDa. 13. The method of claim 1, wherein the scavenger and coating compound has a molecular weight ranging from 15 to 115 kDa. 14. The method of claim 1, wherein the scavenger and coating compound has a molecular weight ranging from 20 to 150 kDa. 15. The method of claim 1, wherein the concentration of the scavenger and coating compound in the solution is 2-20 g/L. 16. The method of claim 1, wherein the concentration of the scavenger and coating compound in the solution is 5 g/L. 17. The method of claim 1, wherein the salt comprises one or more of sodium, potassium, calcium, magnesium, phosphate, hydrogen carbonate, and chloride ions; and the nutrient comprises one or more of a physiologically acceptable carbohydrate, fatty acid, and amino acid. 18. The method of claim 17, wherein the physiologically acceptable carbohydrate is glucose. 19. The method of claim 1, wherein the solution further comprises at least one of the following: a vasodilator; an antibiotic; a fibrinolytic component; a thrombocyte receptor blocker; a hormone; an insulin; a cortisol; a growth hormone; and an anabolic steroid. 20. The method of claim 1, wherein the solution further comprises a pure scavenger compound. 21. The method of claim 1, wherein the solution further comprises papaverine, alteplase, abciximab, tyroxin/triiodotyronin, or a combination thereof. 22. The method of claim 12, wherein the scavenger and coating compound is a dextran compound. 23. The method of claim 13, wherein the scavenger and coating compound is a dextran compound. 24. The method of claim 14, wherein the scavenger and coating compound is a dextran compound.

Details for Patent 8,980,541

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	ACTIVASE	alteplase	For Injection	103172	11/13/1987		2020-11-03
Genentech, Inc.	CATHFLO ACTIVASE	alteplase	For Injection	103172	09/04/2001		2020-11-03
Janssen Biotech, Inc.	REOPRO	abciximab	Injection	103575	12/22/1994		2020-11-03